Strategy

It is our ambition to contribute to global health by the delivery of better adjuvants to impact vaccination campaigns in low- and high-income countries. LiteVax Adjuvant demonstrated unprecedented performance in preclinical models. In clinical trials with seasonal influenza vaccine supplemented with LiteVax Adjuvant, non-inferiority of low antigen-dose  (NCT05581407) and superiority of  standard antigen dose in elderly (NCT06294262) was confirmed.

cGMP adjuvant product is available as a ready-for-use aqueous formulation for preclinical and clinical studies. Preclinical and clinical data are available as part of our licensing package.

Please contact Luuk Hilgers at luuk.hilgers(at)litevax.com for more information or test material.